Inspire Medical Systems, Inc.
Inspire Medical Systems Announces Q2 2024 Financial Results and New Share Repurchase Program
Summary
Inspire Medical Systems, Inc. reported a 30% year-over-year revenue increase for the second quarter of 2024, reaching $195.9 million. The company also activated 81 new U.S. centers and created 12 new U.S. sales territories. Inspire's Board of Directors authorized a share repurchase program of up to $150.0 million of the company's outstanding shares of common stock. The company increased its full-year 2024 revenue guidance to between $788 million to $798 million and diluted net income per share guidance to between $0.60 to $0.80 per share.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement